uniQure N.V. (QURE) Shareholder Equity
- 2026-03-31: Common Stock, Value, IssuedUSD $3.73M; Additional Paid in CapitalUSD $1.59B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-59.88M; Retained Earnings (Accumulated Deficit)USD $-1.38B.
- 2025-12-31: Common Stock, Value, IssuedUSD $3.69M; Additional Paid in CapitalUSD $1.58B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-58.22M; Retained Earnings (Accumulated Deficit)USD $-1.33B.
- 2025-09-30: Common Stock, Value, IssuedUSD $3.68M; Additional Paid in CapitalUSD $1.58B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-58.74M; Retained Earnings (Accumulated Deficit)USD $-1.29B.
- 2025-06-30: Common Stock, Value, IssuedUSD $3.25M; Additional Paid in CapitalUSD $1.26B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-58.90M; Retained Earnings (Accumulated Deficit)USD $-1.21B.
uniQure N.V. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD |
|---|---|---|---|---|---|---|
| 2026-03-31 | $3.73M | $1.59B | $-59.88M | $-1.38B | $149.34M | 3 month · $5.09M |
| 2025-12-31 | $3.69M | $1.58B | $-58.22M | $-1.33B | $198.90M | 12 month · $17.68M |
| 2025-09-30 | $3.68M | $1.58B | $-58.74M | $-1.29B | $228.75M | 3 month · $3.52M 9 month · $13.02M |
| 2025-06-30 | $3.25M | $1.26B | $-58.90M | $-1.21B | $-4.00M | 3 month · $5.08M 6 month · $9.49M |
| 2025-03-31 | $3.24M | $1.26B | $-53.80M | $-1.17B | $33.69M | 3 month · $4.41M |
| 2024-12-31 | $2.94M | $1.17B | $-52.80M | $-1.13B | $-6.75M | 12 month · $22.26M |
| 2024-09-30 | $2.93M | $1.17B | $-56.70M | $-1.06B | $55.82M | 3 month · $3.44M 9 month · $17.51M |
| 2024-06-30 | $2.93M | $1.16B | $-56.32M | $-1.01B | $97.11M | 3 month · $6.88M 6 month · $14.07M |
| 2024-03-31 | $2.92M | $1.16B | $-56.04M | $-956.03M | $146.75M | 3 month · $7.19M |
| 2023-12-31 | $2.88M | $1.15B | $-53.55M | $-890.41M | $207.67M | 12 month · $35.09M |
| 2023-09-30 | $2.88M | $1.14B | $-58.56M | $-817.20M | $268.78M | 3 month · $11.10M 9 month · $28.05M |
| 2023-06-30 | $2.88M | $1.13B | $-52.44M | $-727.63M | $353.32M | 3 month · $8.89M 6 month · $16.95M |
| 2023-03-31 | $2.87M | $1.12B | $-52.49M | $-659.16M | $412.77M | 3 month · $8.06M |
| 2022-12-31 | $2.84M | $1.11B | $-58.30M | $-581.93M | $476.01M | 12 month · $34.20M |
| 2022-09-30 | $2.83M | $1.10B | $-93.00M | $-588.74M | $421.17M | 3 month · $7.61M 9 month · $22.29M |
| 2022-06-30 | $2.82M | $1.09B | $-67.63M | $-540.88M | $486.49M | 3 month · $7.81M 6 month · $14.68M |
| 2022-03-31 | $2.82M | $1.08B | $-39.31M | $-501.82M | $546.00M | 3 month · $6.87M |
| 2021-12-31 | $2.80M | $1.08B | $-28.90M | $-455.14M | $595.78M | 12 month · $25.64M |
| 2021-09-30 | $2.80M | $1.07B | $-17.88M | $-463.35M | $590.75M | 3 month · $5.96M 9 month · $18.75M |
| 2021-06-30 | $2.79M | $1.06B | $-4.59M | $-426.82M | $633.61M | 3 month · $7.03M 6 month · $12.79M |
| 2021-03-31 | $2.78M | $1.05B | $2.35M | $-826.29M | $228.69M | 3 month · $5.76M |
| 2020-12-31 | $2.71M | $1.02B | $-9.90M | $-784.73M | $243.91M | 12 month · $21.83M |
| 2020-09-30 | $2.69M | $1.01B | $2.33M | $-784.03M | $227.89M | 3 month · $6.37M 9 month · $16.45M |
| 2020-06-30 | $2.69M | $1.00B | $-7.32M | $-730.26M | $265.50M | 3 month · $5.72M 6 month · $10.08M |
| 2020-03-31 | $2.68M | $992.14M | $-11.97M | $-687.71M | $295.15M | 3 month · $4.36M |
| 2019-12-31 | $2.65M | $986.80M | $-6.70M | $-659.71M | $323.06M | 12 month · $17.53M |
| 2019-09-30 | $2.65M | $980.55M | $-14.68M | $-618.28M | $350.23M | 3 month · $3.88M 9 month · $12.76M |
| 2019-06-30 | $2.33M | $732.92M | $-8.52M | $-594.68M | $132.06M | 3 month · $4.59M 6 month · $8.89M |
| 2019-03-31 | $2.32M | $727.79M | $-9.73M | $-563.28M | $157.11M | 3 month · $4.29M |
| 2018-12-31 | $2.30M | $720.07M | $-7.26M | $-535.51M | $179.61M | 12 month · $10.71M |
| 2018-09-30 | $2.29M | $716.66M | $-5.49M | $-513.62M | $199.85M | 3 month · $2.62M 9 month · $7.35M |
| 2018-06-30 | $2.29M | $712.40M | $-4.69M | $-491.58M | $218.42M | 3 month · $2.21M 6 month · $4.73M |
| 2018-03-31 | $1.97M | $570.60M | $-1.31M | $-470.99M | $100.26M | 3 month · $2.53M |
| 2017-12-31 | $1.95M | $566.53M | $-3.80M | $-475.32M | $89.36M | 12 month · $10.28M |
| 2017-09-30 | $1.61M | $471.65M | $-5.81M | $-447.84M | $19.61M | 9 month · $5.98M |
| 2017-06-30 | $1.61M | $469.10M | $-5.83M | $-437.60M | $27.29M | 6 month · $3.53M |
| 2017-03-31 | $1.60M | $466.69M | $-6.24M | $-416.33M | $45.73M | 3 month · $1.60M |
| 2016-12-31 | $1.59M | $464.65M | $-6.56M | $-396.06M | $63.63M | 12 month · $6.21M |
| 2015-12-31 | $1.54M | $455.90M | $-6.83M | $-322.68M | $127.93M | 12 month · $11.62M |
| 2014-12-31 | (m) | (m) | (m) | (m) | $42.63M | 12 month · $8.40M |
| 2013-12-31 | (m) | (m) | (m) | (m) | $2.29M | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |